Abstract
A new rat model of the Schwartz--Bartter syndrome was created by the administration of 1-deamino-8-D-arginine vasopressin together with a forced water intake. The treatment led to water retention, hypernatriuria, marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(beta-mercapto-beta, beta-cyclopentamethylene-propionic acid)- 2-o-ethyltyrosine-4-valine] arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz--Bartter syndrome.
| Original language | English |
|---|---|
| Pages (from-to) | 333-339 |
| Number of pages | 7 |
| Journal | Acta Medica Hungarica |
| Volume | 43 |
| Issue number | 3 |
| Publication status | Published - 1986 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Experimental water intoxication induced by dDAVP in rat, and its prevention with the vasopressin antagonist d(CH2)5Tyr(Et)VAVP. / László, F.; Baláspiri, L.
In: Acta Medica Hungarica, Vol. 43, No. 3, 1986, p. 333-339.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Experimental water intoxication induced by dDAVP in rat, and its prevention with the vasopressin antagonist d(CH2)5Tyr(Et)VAVP.
AU - László, F.
AU - Baláspiri, L.
PY - 1986
Y1 - 1986
N2 - A new rat model of the Schwartz--Bartter syndrome was created by the administration of 1-deamino-8-D-arginine vasopressin together with a forced water intake. The treatment led to water retention, hypernatriuria, marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(beta-mercapto-beta, beta-cyclopentamethylene-propionic acid)- 2-o-ethyltyrosine-4-valine] arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz--Bartter syndrome.
AB - A new rat model of the Schwartz--Bartter syndrome was created by the administration of 1-deamino-8-D-arginine vasopressin together with a forced water intake. The treatment led to water retention, hypernatriuria, marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(beta-mercapto-beta, beta-cyclopentamethylene-propionic acid)- 2-o-ethyltyrosine-4-valine] arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz--Bartter syndrome.
UR - http://www.scopus.com/inward/record.url?scp=0022832178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022832178&partnerID=8YFLogxK
M3 - Article
VL - 43
SP - 333
EP - 339
JO - Acta Medica Hungarica
JF - Acta Medica Hungarica
SN - 0236-5286
IS - 3
ER -